Health Care·Biotechnology·$20.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.52 | N/A | -136.36% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.52 | N/A | -136.36% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over the company's financial performance this quarter. They reiterated their commitment to long-term objectives.
Management highlighted ongoing challenges in meeting financial expectations.
They emphasized a focus on long-term goals despite current setbacks.
This earnings report indicates that Moderna is facing significant challenges, particularly in its earnings performance. The lack of revenue data and guidance may lead to uncertainty among investors. The stock reaction is not available, but the substantial EPS miss suggests that investor confidence may be impacted.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BAKER HUGHES CO. A Class A
Nov 10, 2008